Power 2 Save

Menu
  • What is Power2Save?
    • What is Power2Save?
      • Our Mission
      • About Organ Transplants
    • Close
  • Education
    • Transplant Community Educational Resources
      • Transplant Fact or Fiction
      • Transplant in 10 Video Series
      • Transplant FAQs
      • Preventing Rejection
        • Transplant Research
          • Current Research
          • Clinical Trials
          • Transplant News
    • Close
  • Get Involved
    • Get Involved
      • Ways to Help
      • Planned Giving and Stock Donations
      • Volunteer
      • Partnership Opportunities
      • Living Donor Circle of Excellence
      • Advocate for Change
        • Advocacy 101
        • Transplant Legislation
        • AST Key Position Statements
      • What is “Public Comment?”
      • Become an Organ Donor
    • Close
  • Community Corner
    • Community Mosaic
      • Power Players
      • Video Stories
      • Share Your Story
      • Keep in Touch
      • Transplant Community Summit
    • Close
  • Living Donor Tool Kit
  • Contribute
Home > Clinical Trials

Clinical Trials

The clinical trials listed below are for informational purposes only and are not endorsed by the AST/Power2Save. More information on clinical trials can be found in our clinical trials brochure. For information about posting a clinical trial, contact JoAnn Gwynn at jgwynn@myast.org.

Clinical Trials for Kidney Recipients

Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as Adjunctive Treatment For Refractory Antibody-Mediated Rejection (ARMOR) in Adult Renal Transplant Recipients
Sponsor: CSL Behring
Organ Type: Kidney
Ages Accepted: 18+
Genders Accepted: Both male and female
Expected Study Completion Date: Thursday, January 15, 2026

A Partially-blinded, Active-controlled, Multicenter, Randomized Study Evaluating Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in de Novo and Maintenance Kidney Transplant Recipients (CIRRUS I)
Sponsor: Novartis
Organ Type: Kidney
Ages Accepted: 18+
Genders Accepted: Both male and female
Expected Study Completion Date: April 15, 2026

Clinical Trials for Other Organ Types

Tabelecleucel for Solid Organ Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)
Sponsor: Atara Biotherapeutics
Organ Type: All organs
Ages Accepted: All ages
Genders Accepted: Both male and female
Expected Study Completion Date: Monday, November 30, 2020
Other Requirements

A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant (RR) to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
Sponsor: Takeda Pharmaceutical Company Limited
Organ Type: Hematopoietic Stem Cell Transplant, All organs
Ages Accepted: ≥12 years of age
Genders Accepted: Both male and female
Expected Study Completion Date: Tuesday, September 29, 2020
Other Requirements

A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Recipients
Sponsor: Takeda Pharmaceutical Company Limited
Organ Type: Hematopoietic Stem Cell Transplant
Ages Accepted: ≥16 years of age
Genders Accepted: Both male and female
Expected Study Completion Date: Tuesday, August 13, 2021
Other Requirements

A 12-month, Open-label, Multicenter, Randomized, Safety, Efficacy, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of an Anti-CD40 Monoclonal Antibody, CFZ533 vs. Standard of Care Control, in Adult de Novo Liver Transplant Recipients With a 12-month Additional Follow-up (CONTRAIL I)
Sponsor: Novartis
Organ Type: Liver
Ages Accepted: 18 years to 70 years
Genders Accepted: Both male and female
Expected Study Completion Date: September 23, 2022

  • © 2023   |   Contact Us   |   Press   |  Privacy Policy |
  • Facebook
  • Instagram
  • Twitter

Copyright © 2023 · Power2Save on Genesis Framework · WordPress · Log in